

Human Tumor Markers

Human Tumor Markers

Biology and Clinical Applications

Proceedings of the
Third International Conference
Lacco Ameno d'Ischia, Naples, Italy
April 23-26, 1986

Editors

F. Cimino · G. D. Birkmayer

J. V. Klavins · E. Pimentel · F. Salvatore



Walter de Gruyter · Berlin · New York 1987

Editors

Filiberto Cimino, M. D., Ph. D.
Professor of Biochemistry and Director
Istituto di Scienze Biochimiche
II Facoltà di Medicina e Chirurgia
Università di Napoli
Via S. Pansini, 5
I-80131 Napoli
Italy

Janis V. Klavins, M. D., Ph. D.
Professor of Pathology
Cornell University Medical College
and Chairman of the Department at the
Catholic Medical Center of Brooklyn and Queens, Inc.
152-11 89th Avenue
Jamaica, New York 11432
U.S.A.

Francesco Salvatore, M. D., Ph. D.
Professor of Biochemistry
Istituto di Scienze Biochimiche
II Facoltà di Medicina e Chirurgia
Università di Napoli
Via S. Pansini, 5
I-80131 Napoli
Italy

George D. Birkmayer, M. D., Ph. D.
Associate Professor of Medicine
and Clinical Chemistry
University of Graz
Laboratory for Bio-Analytic
Schwarzspanierstrasse 16
A-1090 Vienna
Austria

Enrique Pimentel, M. D.
Professor and Director
Centro Nacional de Genetica
Humana y Experimental
Instituto de Medicina Experimental
Universidad Central de Venezuela
Apartado Postal 50587
Caracas 1050-A
Venezuela

Library of Congress Cataloging in Publication Data

Human tumor markers.

Proceedings of the 3rd International Conference of Human Tumor Markers, held under the auspices of the International Academy of Tumor Marker Oncology and the University of Naples.

Includes bibliographies and indexes.

1. Tumor markers--Diagnostic use--Congresses. 2. Cancer--Diagnosis--Congresses. I. Cimino, F. (Filiberto), 1939- II. International Conference of Human Tumor Markers (3rd : 1986 : Lacco Ameno, Italy) III. International Academy of Tumor Marker Oncology. IV. Università di Napoli.

[DNLM: 1. Neoplasms--diagnosis--congresses. W3 IN18HML 3rd 1986h / QZ 241 H9186 1986] RC270.3.T84T86 1987 616.99'407582 87-20075
ISBN 0-89925-307-5 (U.S.)

CIP-Kurztitelaufnahme der Deutschen Bibliothek

Human tumor markers : biology and clin. applications : proceedings of the ... internat. conference. - Berlin ; New York : de Gruyter

3. Lacco Ameno d'Ischia, Napoli, Italy, April 23-26, 1986. - 1987.
ISBN 3-11-010935-2

Copyright © 1987 by Walter de Gruyter & Co., Berlin 30.

All rights reserved, including those of translation into foreign languages. No part of this book may be reproduced in any form - by photoprint, microfilm or any other means nor transmitted nor translated into a machine language without written permission from the publisher. Printing: Gerike GmbH, Berlin. Binding: Lüderitz & Bauer GmbH, Berlin. - Printed in Germany.

PREFACE

The development of cancer is an insidious process, that very often takes a number of years before becoming clinically evident, and no current technique, of any kind, is as sensitive and specific as to detect tumors smaller than one billion of cells. As a consequence, the disease is usually diagnosed in an advanced state, when it is beyond the reach of therapeutic strategies. This is the main obstacle to secondary prevention aimed at reducing the mortality from cancer.

The last decade has seen an explosion of reports dealing with tumor markers, i.e., simple, inexpensive and non-invasive tests able to detect a precocious signal of a neoplasia. Unfortunately, the elation that greeted many reports was often followed by disappointment, because what at first sight seemed to be promising turned out to be applicable only to a limited number of cases. The most probable cause of these failures is that cancer is a multitude of neoplastic diseases in which a number of endogenous and exogenous etiologic factors are involved, either simultaneously or at different times. Therefore, no one single test will be able to diagnose all neoplastic diseases.

Throughout the world scientists involved in both basic and clinical biomedical research are making efforts to identify peculiar aspects of the transformed phenotypes in order to use them as precocious signals of neoplasia. It must be said, however, that despite the great progress that has been made over the last few years, the early diagnosis of cancer is still, with a few exceptions, out of our reach. It is conceivable that a breakthrough will only be seen when the biology of the tumor cell is fully elucidated. In other words, only when the intimate mechanisms of cell transformation are clarified, will we have access to the true signals of a nascent or ongoing neoplastic process.

It was this line of thinking that prompted the 3rd International Congress of Human Tumor Markers that was held under the auspices of the International Academy of Tumor Marker Oncology and of the University of Naples in Lacco Ameno d'Ischia on April 23-26 1986. This volume contains the Proceedings of the Conference in the form of 61 papers that covered the following topics: Molecular Biology of Tumors, Tumor Antigens, Immunochemical Cancer

Characterization, Modified Nucleosides, Management of Human Leukemias, Patient Surveillance, Receptors and Hormones, Enzymes and Isoenzymes. The papers are in the form of either original studies or overview articles containing data pertaining to both experimental and clinical oncology. It is of particular interest that besides articles reporting recent studies on the conventional tumor markers, there are numerous contributions on the "new" tumor markers, such as the oncogenes, and their diagnostic use either to reveal restriction polymorphisms associated with high-risk populations or to determine the prognosis of certain types of cancer.

Credit for the quality of the volume goes, of course, to the individual authors, who must also be applauded for having promptly delivered their papers.

Sincere thanks and gratitude are due to Jean Gilder and Mariarosaria Calabria for the excellent editing of the manuscripts and for the careful preparation of the subject index. The helpful cooperation of the staff of Walter de Gruyter is also acknowledged.

Filiberto Cimino

George D. Birkmayer

Janis V. Klavins

Enrique Pimentel

Francesco Salvatore

CONTENTS

OPENING LECTURES

G. Prodi	
What does "marker" mean?	3
H. Lynch, S. Lanspa, W. Kimberling, J. Lynch, J. Marcus, G. Schuelke, I. Wells, R. Fusaro, G. Cristofaro, M. Caruso, A. Attolini, G. Di Matteo, P. Giorgio, I. Giorgio	
Biomarkers and colorectal cancer genetics: Lynch syndromes I and II	13
W. J. Boyle and M. A. Baluda	
The human <u>c-myb</u> proto-oncogene product: Identification and detection in immature lymphoid, erythroid, and myeloid cells	33

MOLECULAR BIOLOGY OF TUMOR MARKERS

E. Pimental	
Update on proto-oncogenes and human cancer	49
E. De Vendittis, O. Fasano	
Regulation of the adenylate cyclase activity of <u>CR14</u> yeast mutants by GTP and GDP	65
M. A. Pierotti, G. Della Porta	
Restriction fragment length polymorphisms (RFLPs) as genetic tumor markers	71
A. Eva, S. Srivastava, G. Vecchio, D. Ron, S. Tronick, S. Aaronson	
<u>dbl</u> : A new transforming gene isolated from a human diffuse B-cell lymphoma	83
Th. Gronau, A. Barnekow, A. Anders, F. Anders	
Deregulated oncogenes as markers for melanoma formation in <u>Xiphophorus</u>	93
C. Pietropaolo, M. Dürr, S. Fasano, S. De Falco, G. Russo	
Gene modulation by tumor promoters	101

VIII

- F. Wong-Staal
Molecular analysis of HTLV-III and development of
diagnostic and vaccine reagents for AIDS 117

- F. M. Buonaguro, A. Taeschner, J. K. McDougall, D. A.
Galloway
Transforming properties of human cytomegalovirus 129

TUMOR ANTIGENS

- V. M. Fazio, V. Manzari, A. Faggioni, P. Marchei, M. Lazzari,
A. Redler, I. Antonozzi, L. Frati
Genomic markers of tumors 151

- K. B. Björklund, V. Björklund, M. Brunkener, H. Grönlund,
M. Back
The enigma of a human tumor marker: TPA revisited 169

- H. Hirai, H. Taga, H. Kaneda, H. Ishizuka, Y. Kamata, T.
Koji, N. Ishii, Y. Tsukada, E. Hurwitz, M. Sela, K. Hara,
K. Katoh, Y. Umemoto, T. Shima
Alpha-Fetoprotein: Its diagnostic specificity and
therapeutic use of its antibody 181

- H. Busch, R. K. Busch, P. K. Chan, A. Chatterjee, J. Freeman,
B. Ross, A. Black, M. Yaneva
Nucleolar antigens in cancer tissues 203

- J. V. Klavins
Possible relationship of mouse mammary tumor virus (MMTV)
to human cytotrophoblast 223

- H. J. Staab
Tumor associated antigens for indication and control of
therapy 229

- M. K. Schwartz
Tumor markers in the patient with lung cancer 241

- M. Lüthgens, G. Schlegel
TPA and CEA. 7 years of clinical experience 255

- A. Burlina, M. Plebani, C. Fabbris, D. Basso, G. Del Favero,
R. Naccarato
Biochemical markers in pancreatic cancer diagnosis 267

R. J. Ablin, J. M. Bartkus, M. J. Gonder, J. Polgar	
Factors contributing to suppression of tumour-host responsiveness	279
S. Sell	
Alphafetoprotein: The epitome of cancer markers	301
G. F. Springer, P. R. Desai, H. Tegtmeyer, W. A. Fry,	
R. A. Semerdjian, E.F. Scanlon, A. Klein-Szanto	
Responses of patients to their carcinoma-associated T and Tn-specific antigens	315
H. Denk	
Intermediate filaments and desmosome-associated proteins (desmoplakins) in morphologic tumor diagnosis	333

IMMUNOCHEMICAL CANCER CHARACTERIZATION

A. A. Sandberg, C. Turc-Carel	
Chromosomes as human tumor markers	355
M. I. Colnaghi, S. Andreola, A. Diotti, S. Ménard, S. Miotti,	
S. Orefice, S. Pupa, E. Tagliabue	
Immunodiagnosis of human carcinomas using monoclonal antibodies	377
S. Ghielmi, G. Mantero, A. Albertini, D. Gamba, C. Capella	
Use of hCG monoclonals in RIA methods and immuno-histochemistry	387
M. Temponi, M. Matsui, M. Kusama, M. Tsujisaki, P. G. Natali,	
S. Ferrone	
Monoclonal antibody defined markers of human melanoma cells	403
S. von Kleist	
A molecular analysis of the carcinoembryonic antigen (CEA) by monoclonal antibodies	415
M. Moore, A. K. Ghosh	
MHC status of primary human colorectal carcinoma	421
P. M. Capone, C. A. Bergmann, L. D. Papsidero, T. Ming Chu	
Assessment of tumor associated monoclonal antibody in immunotherapy in a syngeneic model	435

MODIFIED NUCLEOSIDES

- F. Salvatore, M. Savoia, T. Russo, L. Sacchetti, F. Cimino
Pseudouridine in biological fluids of tumor-bearing patients 451
- F. Cimino, T. Russo, A. Colonna, A. Duilio, R. Ammendola,
F. Costanzo, A. Oliva, F. Esposito, F. Salvatore
Pseudouridine excretion in experimental neoplasias of retroviral origin 463
- C. W. Gehrke, K. C. Kuo
High resolution quantitative RP-HPLC-UV of nucleosides in RNAs, DNAs and mRNAs 475
- E. Schlimme, K.-S. Boos, B. Wilmers, H. J. Gent
Analysis of ribonucleosides in human body fluids and their possible role as pathobiochemical markers 503
- K. C. Kuo, F. Esposito, J. E. McEntire, C. W. Gehrke
Nucleoside profiles by HPLC-UV in serum and urine of controls and cancer patients 519
- O. K. Sharma, F. L. Buschman, E. Borek, D. L. Cohn,
K. A. Penley, F. N. Judson, B. S. Dobozin, K. M. Zunich,
C. H. Kirkpatrick
Aberrant urinary excretion of modified nucleosides in patients with various manifestations of infection with HTLV-III/LAV 545

MANAGEMENT OF HUMAN LEUKEMIAS

- F. Pandolfi, A. Cafaro, I. La Cesa
Activation of cellular oncogenes following chromosomal rearrangements as a possible pathogenetic mechanism in HTLV-I positive and negative T-helper-phenotype CLL 561
- B. Rotoli, G. De Rosa, L. Catalano, C. Selleri
Therapeutic options in acute leukemias 569
- R. Foa, M. T. Fierro, F. Gavosto, N. Migone, G. Basso,
E. Madon, M. Saitta, F. Lauria, G. Paolucci, P. Foa,
R. Schirò, G. Masera, G. Pizzolo
Characterization of human non-T acute lymphoblastic leukaemia: Results of a multicentre study 585

- G. Scala, F. Alfinito, G. Morrone, M. Tamburrini, G. D'Alessio,
C. I. Pastore, F. Ferrara, S. Venuta
Human interleukin 1 (IL1) and interleukin 2 (IL2) can
function as autocrine growth factors for some neoplastic
human lymphoid cells 599

PATIENT SURVEILLANCE

- F. Montinari, G. Pancera, M. Merrino, G. Luporini, F. Pozzi,
S. Perolini, C. Petrini
Long term follow-up and therapy monitoring of cancer:
Is the simultaneous dosage of CEA and TPA useful? 613

- J. G. D. Birkmayer, B. Paletta
New strategies for follow up of breast cancer patients
using CEA, TPA, CA 15-3 and CA 50 621

- L. Santamaria, R. Pizzala, G. B. Galioto, M. Benazzo,
A. Bianchi, M. C. Casella, G. Bianchi, U. Ambanelli,
G. Santagati
Serum lipid sialic acid (LASA) test in detection and
monitoring of malignancies, paraneoplastic and rheumatoid
syndromes 631

- M. Paganuzzi, M. Onetto, P. Marroni, G. Valenti, F. Boccardo,
L. Santi
Clinical evaluation of new tumor-associated antigens 643

- M. Salvatore, S. Lastoria, L. Mansi
An overview of results. Future perspectives of
radioimmunodetection 657

- G. L. Buraggi
Tumor imaging with radiolabelled antibodies 663

RECEPTORS AND HORMONES

- M. F. Stewart, A. White, J. G. Ratcliffe
Hormones in lung cancer 675

- F. Pacini, R. Elisei, D. Taddei, S. Anelli, A. Pinchera
Clinical validation of immunoradiometric assay for
measuring serum thyroglobulin in anti-thyroglobulin
autoantibody positive sera in patients with thyroid
cancer 695

- V. Macchia, A. Mariano, P. Laccetti
Alterations of membrane TSH-receptor in thyroid tumors 701
- A. Weisz, N. Medici, F. Bresciani
Binding of the estrogen receptor to defined regions of
the estrogen responsive chicken ovalbumin gene and
construction of a consensus sequence for the DNA site
which binds the receptor 717
- J. Caselitz, G. Seifert
New developments in tumor markers and receptors in head
and neck tumors 731
- F. Auricchio, A. Migliaccio, A. Rotondi, G. Castoria,
M. Di Domenico, M. Pagano
Regulation of hormone binding of 17 β -estradiol receptor
by tyrosine phosphorylation and phosphotyrosine dephos-
phorylation of the receptor 755

ENZYMES AND ISOENZYMES

- S. Pontremoli, E. Melloni
Selective protein phosphorylation by protein kinase C
in cell activation 787
- L. A. Pinna, A. Brunati, D. Saggioro, L. Chieco-Bianchi
Protein kinase activities of normal and transformed
lymphocytes 803
- F. Della Ragione, M. Carteni-Farina, V. Gagnaniello, A. Ravel,
V. Zappia
Deficiency of 5'-deoxy-5'-methylthioadenosine phosphorylase
in human leukemia: Biochemical aspects and clinical
implications 817
- D. W. Moss
The role of multiple forms of alkaline phosphatase in
cancer detection and monitoring 829
- G. Federici, A. M. Caccuri, M. Lo Bello, R. Massoud, C. Di Ilio,
G. Del Boccio, A. Aceto
Glutathione transferase as a tumor marker in human breast
carcinoma 845
- J. S. King
Cancer-related changes in creatine kinase isoenzymes and
variants 857

M. G. Paggi, A. Caputo Clinical significance of a rearranged hexokinase isozymes expression in neoplastic phenotype: The astrocytoma model	869
I. Mavelli, G. Rotilio, M. R. Ciriolo, G. Melino, O. Saporà Antioxygenic enzymes as tumor markers: A critical reassessment of the respective roles of superoxide dismutase and glutathione peroxidase	883
P. Izzo, P. Costanzo, A. Lupo, F. Salvatore Novel aspects of human aldolase gene family and its expression in tumor cells	889
AUTHOR INDEX	899
SUBJECT INDEX	905

OPENING LECTURES

1911

1911

WHAT DOES "MARKER" MEAN?

G. Prodi

Istituto di Cancerologia, Università di Bologna, Viale Filopanti 22,
40126 Bologna, Italy

Introduction

Generally, when we speak of a "tumor marker" we mean a condition related to a tumor, i.e., the presence of the marker equals the presence of a tumor. The marker allows us to find the tumor when it is still asymptomatic (by mass screening), or we can follow its natural history, its relapse, or the appearance of metastases. The same concept applies to preneoplastic lesions. In fact, the marker can be useful in determining the risk, and hence in individuating groups that should be studied in greater detail.

A marker, therefore, is a sign, a state that stands for something else under some aspect or quality, to use an expression coined by Peirce:

As any clinical symptom or laboratory finding, a tumor marker can be considered under three aspects. The first is the semeiotic aspect, whereby a sign is meaningful within the framework of a code. The second aspect is according to the informational theory whereby such a sign is viewed in the light of the information that it provides with regard to the implication sought, and thus it is associated to other signs and distinct from them. The third aspect is that of communication theory, where the sign is a material condition emanating from a source and brought by a channel to a receiver. These three aspects are closely related because communication and information are intrinsic to the nature of the sign and code.

Semeiotic Prospectives

In semeiotics, a condition that stands for another in purely material terms (like smoke for fire, as smoke comes from fire, therefore it is associated to it) is distinguished from a condition that stands for another in

conventional and discursive terms (like a word in relation to its reference -- object). The former is called "signal" and the second "sign". They are distinct from each other because one is a material implication, the other a codified relationship. However, I believe there is a misunderstanding in this distinction. In physics, things are as they are, and we have to admit that fire produces smoke, at least on some occasions. All material events are chains of implications and also our neurologic ability to understand them cognitively is formed by chains of implications, albeit very complex and obscure. But in terms of cognitive understanding, the signal is not at all distinguishable from the sign: smoke equals fire only when there is a connection verified empirically that establishes a cognitive fact. Thus, within the framework of a theory, a signal is also a sign. The only difference is that smoke and fire are apparently so closely related that the underlying theory is, at first sight, almost invisible. Therefore, they are often confused with the objective reality that forms their reference. For other aspects of knowledge, the connection is more complex, because their theory is wider and sometimes more uncertain.

When we speak of smoke as a signal of fire, we refer to a relationship among words. This connection is conventional, as is easily demonstrated by citing cases in which fire does not produce smoke or smoke is without fire. In turn, words are connected to reality by way of an empiric habitual framework, which is codified and made fluent. Thus, also words are material operations.

A clinical symptom, in our case a tumor marker, is a sign that is meaningful only within a previously established theory. The relationship with the objective reference "for which it stands" (in this case, the tumor) is not direct and biunivocal, but it is mediated and certified by a wider and empirically established theory. This demonstrates that the sign "stands for" something else. As any sign, a clinical symptom is significant in a system that we can call theory, code, language, or science, i.e., a coherent whole of organized knowledge, working a priori like a system of reference and decodification. The interpretative problem arises when the relationship between a signal or sign and its theory is equivocal or not univocally established, either because the theory is still weak or because the sign is indistinct. Now we shall consider the first case and leave the question of distinction and clarity of signal to the next two points.

We can establish a very strong theory and include in it all the signs that are such because of the theory itself. The theory can be pure fantasy. The history of medicine provides numerous examples of such theories: the connection of humour and stars, and fluxes and horoscopes. In this context, even the hour of birth, even the most irrelevant facts become precise signs. The theory is incorrect because the system of empiric connection of it with the referent (with the field of reality, in particular with disease and the body) is inappropriate or inexistant: but the interpretation of the sign may be univocal and precise.

Since science has placed as limit to the construction of any theory the continuous compatibility with facts, by way of experimentation, things have become more difficult. Facts have not eliminated the need for the theoretical framework, which is always the indispensable mediator for all human interpretations. But the adherence to reality is linked to the fact that the framework, in any scientific sector, is in continual movement, that it is always transformed because it is always imperfect in relation to the data found, and only in well consolidated sectors does a sign find an adequate theory, that is a linguistic framework of satisfying and unambiguous correspondence with reality. The situation is different in ordinary language, where daily use necessarily produces a satisfactory relationship between the signs that we continuously use and their interpretation in the terms of ordinary language.

In the field we are now considering, a marker would be an unambiguous sign of cancer in the framework of a theory that was previously defined: A) the specificity of the tumor condition with respect to any other condition in, or occurrence of the organism; B) the link between the considered marker and that specificity. Only in this way would the data observed "stand for" the tumor -- would it assume the character of the sign.

Unfortunately, such a theory does not yet exist. Cancer research may be defined as an uninterrupted search to define qualitatively distinct and specific traits of the tumor cell. What has been defined as "qualitative" (by Warburg up to the recent immunological studies, and the still more recent oncogene theory) has always been interpreted as "quantitative", that is, as "more or less". The tumor cell is highly mimetic, and it is relatively invulnerable for the same reason as it has such ambiguous